Materials Map

Discover the materials research landscape. Find experts, partners, networks.

  • About
  • Privacy Policy
  • Legal Notice
  • Contact

The Materials Map is an open tool for improving networking and interdisciplinary exchange within materials research. It enables cross-database search for cooperation and network partners and discovering of the research landscape.

The dashboard provides detailed information about the selected scientist, e.g. publications. The dashboard can be filtered and shows the relationship to co-authors in different diagrams. In addition, a link is provided to find contact information.

×

Materials Map under construction

The Materials Map is still under development. In its current state, it is only based on one single data source and, thus, incomplete and contains duplicates. We are working on incorporating new open data sources like ORCID to improve the quality and the timeliness of our data. We will update Materials Map as soon as possible and kindly ask for your patience.

To Graph

1.080 Topics available

To Map

977 Locations available

693.932 PEOPLE
693.932 People People

693.932 People

Show results for 693.932 people that are selected by your search filters.

←

Page 1 of 27758

→
←

Page 1 of 0

→
PeopleLocationsStatistics
Naji, M.
  • 2
  • 13
  • 3
  • 2025
Motta, Antonella
  • 8
  • 52
  • 159
  • 2025
Aletan, Dirar
  • 1
  • 1
  • 0
  • 2025
Mohamed, Tarek
  • 1
  • 7
  • 2
  • 2025
Ertürk, Emre
  • 2
  • 3
  • 0
  • 2025
Taccardi, Nicola
  • 9
  • 81
  • 75
  • 2025
Kononenko, Denys
  • 1
  • 8
  • 2
  • 2025
Petrov, R. H.Madrid
  • 46
  • 125
  • 1k
  • 2025
Alshaaer, MazenBrussels
  • 17
  • 31
  • 172
  • 2025
Bih, L.
  • 15
  • 44
  • 145
  • 2025
Casati, R.
  • 31
  • 86
  • 661
  • 2025
Muller, Hermance
  • 1
  • 11
  • 0
  • 2025
Kočí, JanPrague
  • 28
  • 34
  • 209
  • 2025
Šuljagić, Marija
  • 10
  • 33
  • 43
  • 2025
Kalteremidou, Kalliopi-ArtemiBrussels
  • 14
  • 22
  • 158
  • 2025
Azam, Siraj
  • 1
  • 3
  • 2
  • 2025
Ospanova, Alyiya
  • 1
  • 6
  • 0
  • 2025
Blanpain, Bart
  • 568
  • 653
  • 13k
  • 2025
Ali, M. A.
  • 7
  • 75
  • 187
  • 2025
Popa, V.
  • 5
  • 12
  • 45
  • 2025
Rančić, M.
  • 2
  • 13
  • 0
  • 2025
Ollier, Nadège
  • 28
  • 75
  • 239
  • 2025
Azevedo, Nuno Monteiro
  • 4
  • 8
  • 25
  • 2025
Landes, Michael
  • 1
  • 9
  • 2
  • 2025
Rignanese, Gian-Marco
  • 15
  • 98
  • 805
  • 2025

Smith, Fang G.

  • Google
  • 1
  • 6
  • 1

University of Birmingham

in Cooperation with on an Cooperation-Score of 37%

Topics

Publications (1/1 displayed)

  • 2013S96 Simvastatin as an adjuvant therapy for infection and sepsis-in-vitro and in-vivo studies suggest pre-emptive / early therapy in the elderly1citations

Places of action

Chart of shared publication
Thickett, David
1 / 1 shared
Sapey, Elizabeth
1 / 2 shared
Walton, Georgia
1 / 1 shared
Patel, Jaimin
1 / 1 shared
Greenwood, H.
1 / 1 shared
Lord, Janet
1 / 2 shared
Chart of publication period
2013

Co-Authors (by relevance)

  • Thickett, David
  • Sapey, Elizabeth
  • Walton, Georgia
  • Patel, Jaimin
  • Greenwood, H.
  • Lord, Janet
OrganizationsLocationPeople

article

S96 Simvastatin as an adjuvant therapy for infection and sepsis-in-vitro and in-vivo studies suggest pre-emptive / early therapy in the elderly

  • Thickett, David
  • Sapey, Elizabeth
  • Walton, Georgia
  • Smith, Fang G.
  • Patel, Jaimin
  • Greenwood, H.
  • Lord, Janet
Abstract

Ageing is associated with increased episodes of sepsis and poorer outcomes. Statins are associated with improved outcomes during infection. We aimed to characterise the impact of age and acute severe infection on key neutrophil functions, assess whether physiologically relevant doses of simvastatin altered neutrophil functions and if benefits were seen, when during a septic episode statins could be utilised. MethodsNeutrophils from healthy volunteers and patients with lower respiratory tract infections (LRTI), pneumonia and sepsis were assessed for migratory accuracy, phagocytosis and neutrophil extracellular trap production before and after in-vitro treatment with simvastatin. Healthy elderly volunteers received 80mg simvastatin or placebo in a cross over double-blind randomised controlled trial and neutrophil functions were assessed. Data presented is for migration. ResultsNeutrophils from healthy subjects (n = 70, aged 21-94) demonstrated preserved neutrophil movement) (R2 = -0.48, p <0.0001) towards chemoattractants (data shown for IL-8). Neutrophil chemotaxis decreased after 60yrs (comparing 65yrs: mean difference (MD)1.25m/min, p = 0.02). There was a progressive decrease in neutrophil chemotaxis in old patients with a LRTI, pneumonia and severe sepsis (MD compared to healthy control; LRTI (n = 10), 0.7m/min, p = 0.04; pneumonia (n = 5), MD1.1m/min, p = 0.02; sepsis (n = 22) MD1.6m/min, p = 0.01) with "septic neutrophils" unable to mount targeted chemotaxis. Improvements to baseline were seen following recovery. In-vitro treatment of neutrophils from healthy older people with simvastatin (1{micro}M) restored "old" neutrophil chemotaxis to that of "young" cells. Simvastatin also restored neutrophil migration from old patients with LRTI and pneumonia to baseline but not in patients with sepsis. Two weeks of oral simvastatin 80mg once daily therapy in healthy old volunteers (Age>65,n = 20) increased the accuracy of neutrophil migration (MD1.68m/min, p = 0.02) replicating benchwork. Conclusions"Elderly" neutrophil function is compromised in health, and deteriorates during infective episodes, in accordance with the severity of the insult. Migratory accuracy can be improved with simvastatin therapy however neutrophil function in sepsis patients cannot be modulated during short term in-vitro therapy. Our data suggest statin therapy might be a preventative or an early adjuvant intervention rather than a treatment in established sepsis. We are testing whether simvastatin 80mg for seven days modifies neutrophil responses in elderly patients with pneumonia and sepsis (SNOOPI Trial). F1"> WIDTH=200 HEIGHT=133 SRC="/small/S96_F1.gif" ALT="Figure 1"> View larger version (8K): F1590493F1Abstract S96 Figure 1. Simavastatin 80mg once daily for 14 days improves directional migration (chemostaxis) of neutrophils from healthy elderly volunteers towards IL-8. *Students t-Test

Topics
  • impedance spectroscopy
  • molecular dynamics
  • aging